

StemCells

Trial update

Phase II trials underway

StemCells has announced transplantation of the first patient in a recently initiated Phase II trial, evaluating its human central nervous system stem cells (HuCNS-SC) as a treatment for dry age-related macular degeneration (AMD). Progression into the Phase II RADIANT trial was supported by the top-line results of its Phase I/II dose-ranging trial in dry AMD announced in June. Additionally, the company began dosing the first cohort in its Phase II PATHWAY study in cervical spinal cord injuries (SCI) earlier this year. At a price of \$0.41, the shares offer considerable potential, currently trading significantly below our risk-adjusted fair value of \$1.82 per share.

| Year end | Revenue (\$m) | PBT* (\$m) | EPS* (\$) | DPS (\$) | P/E (x) | Yield (%) |
|----------|---------------|------------|-----------|----------|---------|-----------|
| 12/13 | 1.2 | (29.7) | (0.68) | 0.0 | N/A | N/A |
| 12/14 | 1.0 | (32.2) | (0.56) | 0.0 | N/A | N/A |
| 12/15e | 0.2 | (34.1) | (0.35) | 0.0 | N/A | N/A |
| 12/16e | 0.2 | (35.2) | (0.33) | 0.0 | N/A | N/A |

Note: *PBT and EPS are normalized, excluding intangible amortization, exceptional items and share-based payments.

Transplantation of first patient in Phase II in dry AMD

Final results of the 15-patient Phase I/II AMD trial investigating safety and efficacy of sub-retinal transplantation of HuCNS-SC were presented on 26 June at the Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Stockholm, supporting progression into Phase II. The trial met its primary endpoint showing favorable safety and tolerability, also showing improvements in visual function as measured by best-corrected visual acuity (BCVA) and contrast sensitivity. However, the progression of geographic atrophy (GA) was obfuscated by complex and subjective readouts in a largely unrepresentative patient population. The recently initiated Phase II study will encompass a more homogenous study population with patients with less advanced disease (and more measurable GA).

Patent infringement case reaches resolution

StemCells' share price has also been negatively affected by the recently announced dismissal of its patent infringement case against Neuralstem by the US Federal District Court of Maryland. StemCells had hoped to gain sole ownership over six patents related to its human neural stem cells. While disappointing for the company, the decision should have little direct impact on its ongoing clinical trial programs.

Valuation: \$198m from \$205m

On 6 August, StemCells reported Q215 results, which were generally in line with our expectations. Our DCF-based valuation of \$198m (\$1.82 per share) is adjusted only slightly from \$205m (\$1.95 per share) mainly on cash usage over the quarter. We do not include potential share dilution from current out-of-the-money warrants and restricted stock. The company's cash runway should enable operations to be funded into 2016.


Pharma & biotech

1 September 2015

Price **\$0.41**
Market cap **\$44m**

| | |
|--------------------------------|--------|
| Net cash (\$m) at 30 June 2015 | 26.4 |
| Shares in issue | 108.5m |
| Free float | 93% |
| Code | STEM |
| Primary exchange | NASDAQ |
| Secondary exchange | N/A |

Share price performance



Business description

StemCells is a US biotech company developing stem cell-based therapeutics. The lead clinical programme is based on HuCNS-SC (human neural stem cells) for spinal cord injury (SCI) and dry age-related macular degeneration (AMD), both in Phase II trials.

Next events

| | |
|---|------|
| Interim six-month data PATHWAY study (cohort 1) in cervical SCI | Q415 |
| Final Phase II PATHWAY results (cervical SCI) | 2017 |
| Final Phase II RADIANT results (dry AMD) | 2017 |

Analysts

| | |
|-------------------|---------------------|
| Katherine Genis | +1 646 653 7026 |
| Christian Glennie | +44 (0)20 3077 5727 |

healthcare@edisongroup.com

[Edison profile page](#)

Two Phase II trials in areas with major unmet need

StemCells is steadily progressing its pipeline of proprietary human central nervous system stem cells (HuCNS-SC), focusing on CNS disorders. Trials in its two lead indications, spinal cord injuries (SCI) and dry age-related macular degeneration (AMD) have now moved from early and encouraging dose-finding and initial efficacy to larger Phase II studies powered for proof of concept. Both studies are expected to deliver full and final results in 2017.


- Enrolment has started in a Phase II study in GA of age-related AMD. The study was supported by final results presented in June of a Phase I/II study showing good safety tolerability with promising efficacy in a subpopulation of the patient population with a less advanced stage of the disease (and targeted in the Phase II design).
- The ongoing Phase II PATHWAY trial in spinal cord injury has been enrolling its second cohort in the study from early June, while Health Canada has provided approval for an additional site in Canada, adding to the existing eight sites in the US. Interim results are expected in Q415.

Progression in dry AMD


Phase I/II presented at ISSCR

Final results of the 15-patient [Phase I/II](#) AMD trial investigating safety and efficacy of subretinal transplantation of HuCNS-SC were presented on 26 June at the Annual Meeting of the ISSCR in Stockholm. The trial was initiated on the basis of significant indicative preclinical efficacy, as evidenced in an in vivo rat model of AMD, showing that implantation of the HuCNS-SC cells could protect the at-risk cells of the macula from death and prevent or slow down vision loss. The multi-center, open-label, dose-escalation Phase I/II trial consisted of three cohorts, each receiving a different number of cells: Group 1a received 200,000 cells and Group 1b and 2 were given 1m cells. The primary objective was safety including assessment of visual function and disease status by direct retinal examination. The secondary objective, preliminary efficacy, included tests for BCVA, optical coherence tomography (OCT) and fundus autofluorescence (FAF) to measure underlying GA.

The interim and preliminary final study analysis of the Phase I/II trial showed improvements in terms of visual function, as measured by BCVA and contrast sensitivity. Gains in contrast sensitivity (a measure that helps people drive at night or gauge the depth of a poorly lit staircase) were seen in the majority of subjects with over half of the participants showing an improvement of two or more three letter group gains in contrast sensitivity based on the scoring template. Other anatomic assessments were encouraging where increased macular volume and foveal thickness were observed in the study vs fellow eye. The interim and final results also confirmed favorable safety and tolerability.

Exhibit 1: Phase I/II AMD – BCVA at 12 months*


Source: StemCells, ISSCR, 26 June 2015. Note: Vertical axis is growth in lesion size mm².

Exhibit 2: Contrast sensitivity from baseline at 12 months*


Source: StemCells, ISSCR, 26 June 2015. Note: Vertical axis shows change in 3 letter group score (each three letter group = 0.15 improvement).


In terms of GA, the interim efficacy results presented in June 2014 were encouraging, and showed a 70% reduction in the rate of GA compared to the control eye (untreated eye of same patient) and a 65% reduction in the rate of GA compared to the expected natural history of the disease following a single 200,000 cell dose. This is especially important as the goal of this therapy is preservation. Even at the lower cell dose, four of the eight patients with 12-months' follow-up (M12) had GA growth rates in the treated eye notably lower than the control eye.

Following the conclusion of the study, two independent analyses of GA (retinal pigment epithelium loss) were conducted for all cohorts, as measured by FAF. A prospective analysis showed an overall strong trend for decreased GA progression in the study eye vs the fellow eye, consistent with the findings in the interim evaluation. However, a further post-hoc analysis did not reveal a similar trend with greater than anticipated variability in the grading of the images. We point out that these analyses are hampered by the open-label nature of the trial, as well as the small sample size, while the high learning capability on tests also confounds data. It is therefore difficult to draw conclusions from the early data.

StemCells subsequently presented further evaluation of the final Phase I/II data in its Q2 earnings call. At that time management emphasized that criteria for the patient population of the Phase I/II

study did not preclude patients with severe and/or advanced disease – patients that would not be included in the subsequent Phase II study focused on efficacy. The study comprised a diverse patient group, which included those with assorted GA lesions and morphology impeding the results. Disparity in the analyses was thought to be mainly on account of measuring the large and complex lesions presented by 10 of the 15 patients in the study, none of which would have met the criteria for the ongoing Phase II efficacy study. Lesions in the patients with advanced disease progression tended to be large and difficult to analyze objectively, particularly given rugged edges of the lesions and in some cases 'island lesions' off the main shaded area. However, favorable data from the five patients with less advanced GA (and which would fit the Phase II criteria) are shown in Exhibit 3 and support the Phase II trial design. The chart demonstrates that the majority of patients had lower growth of lesions in the study vs the fellow eye. Patients will be followed for a further four years as part of a long-term follow-up trial. Overall, the Phase I/II results provided the support for progression into the recently initiated Phase II study, which encompasses a more homogenous study population with patients with less advanced disease (and more measurable GA).

Exhibit 3: Phase I/II AMD Trial – Phase II eligible patients



Source: StemCells Q215 earnings presentation. Note: Reading Center and site GA assessment by FAF change from BL over 12m.

Phase II RADIANT trial initiated in dry AMD with first transplantation

On 20 July, StemCells announced the start of a Phase II trial, RADIANT in GA, the most advanced form of age-related macular degeneration (dry AMD). Transplantation of the company's human neural stem cells was completed at the Retina Foundation of the Southwest for the first patient in the study. The Phase II proof-of-concept study, enrolling 63 patients, is to evaluate both safety and efficacy of the treatments in intervals over 12 months, assessing both anatomic and functional changes. Patients, all suffering bilateral GA-AMD (geographic atrophy associated with age-related AMD in both eyes) will receive subretinal injection of HuCNS-SC cells into the eye with the inferior BCVA. The study aims to show a reduction in disease progression in the treated vs the control or fellow eye, which will remain untreated. During the Q215 results conference call, management spoke of the strong interest by the medical community in the study, for which full enrolment is expected in 2016. Initial top-line data from the trial are expected in mid-2017.

Age-related macular degeneration is a condition that generally affects people over 50 years of age, and increases in prevalence with age. An estimated 18 million people suffer from some form of AMD in the US and the disease is the number one cause of severe vision loss and legal blindness in those over the age of 55. There are two forms of AMD, dry and wet, with all AMD beginning as the dry form, and approximately 10-15% of cases progressing to the wet form. There are a number

of treatments for wet AMD, including anti-VEGF agents such as Lucentis (worldwide FY14 sales \$4bn by Novartis/Roche) and Eylea (WW FY14 sales \$2.8bn by Bayer/Regeneron). There are no approved treatments for dry AMD, which points to the considerable opportunity for an early-entrant treatment. The use of stem cells for ophthalmic indications has generated significant interest owing to the potential restorative power of these cells in a localized and protected environment. There are only a handful of stem cell treatments currently under investigation for dry AMD, of which none is neural, and therefore would likely be complementary to StemCell's implantation therapy.

SCI PATHWAY study approved in Canada

Earlier this year, StemCells commenced dosing of the first cohort of patients in its Phase II 52-patient PATHWAY study in cervical SCI. Safety and early signs of efficacy have been established in thoracic SC in a Phase I/II trial and top-line 12-month results presented at the joint Spinal Cord Society (ISCoS) and American Spinal Injury Association (ASIA) meeting. In early June the scope of the study was expanded, with authorization by Health Canada to expand PATHWAY into Canada, in addition to the eight sites currently actively recruiting in the US. Interim six-month data in the open-label, dose-escalation arm are expected in the first cohort of seven patients by the end of 2015 and will focus on change in motor function in the upper extremities. Full results of all cohorts are anticipated in 2017. We forecast sales to peak at \$290m in 2026 in spinal cord injury in the EU and the US.

Patent infringement case comes to a close

In late July StemCells announced that the longstanding patent infringement suit against Neuralstem on a series of patents, the Weiss and Reynolds patents by name, was dismissed with prejudice by the US Federal District Court of Maryland. The opinion was released on 22 July, ruling that a third-party scientist has been deemed to be co-owner and co-inventor of the six patents in the litigation. The news came as a disappointment to the company, which had hoped to claim full ownership for the patents. However, the suit has no bearing on the current operations of the company and its ongoing clinical trials. StemCells' IP portfolio includes multiple patent families, as well as proprietary expertise. Its CSI program, currently in Phase II trials, is well in advance of Neuralstem's, which is prioritizing the application of its stem cell technology in other disease areas. Neuralstem uses its neural stem technology primarily for treatment in CNS diseases with its lead clinical trial program in major depressive disorder (Phase II to be initiated in 2015), while Phase I trials are ongoing in schizophrenia, amyotrophic lateral sclerosis, CSI (chronic spinal cord injury) and ischemic stroke.

Valuation

Our valuation of StemCells is adjusted slightly to \$198m (\$1.82 per share) from \$205m (\$1.95 per share) primarily as a result of cash use over the quarter. We base our valuation on a sum-of-the-parts DCF applying our standard 12.5% discount rate. We do not include potential share dilution from current out-of-the-money warrants and restricted stock.

Exhibit 4: Valuation model and key assumptions

| Product | Status | Launch | NPV (\$m) | Peak sales (\$m) | Probability of success | Royalty rate | rNPV (\$m) | rNPV/ share (\$) | Key assumptions |
|----------------------|----------|--------|-----------|------------------|------------------------|--------------|------------|------------------|--|
| HuCNS-SC in AMD | Phase II | 2021 | 670 | 2,050 | 25% | 20% | 160 | 1.48 | US - GA annual incidence: 310,000; 15% severe vision loss; 25% peak penetration (2026); 1.5 eyes treated; \$40,000/dose. EU - GA annual incidence: 680,000; 15% severe vision loss; 20% peak penetration (2026); 1.5 eyes treated; \$32,000/dose. |
| HuCNS-SC in SCI | Phase II | 2021 | 87 | 289 | 20% | 20% | 11 | 0.10 | US - SCI annual incidence: 12,500; 25% peak penetration (2026); \$50,000/dose. EU - SCI annual incidence: 10,500; 20% peak penetration (2026); \$40,000/dose. |
| Portfolio total | | | 757 | | | | 171 | 1.58 | |
| Net cash (end Q215)* | | | | | | | 26.4 | 0.24 | |
| Overall valuation | | | | | | | 198 | 1.82 | 108.5m shares outstanding (undiluted) |

Source: Edison Investment Research. Note: *Assuming completion CIRM loan forgiveness in full.

Financials

StemCells reported an operating loss at end June of \$8.5m (vs \$8.0m in Q214), which was generally in line with our expectations. Sales of \$30,000 were reported in the quarter on royalties from licensing agreements. R&D costs moved up on the initiation of two Phase III efficacy trials (PATHWAY and RADIANT), as well as staff enhancements to strengthen clinical capabilities and product development. We continue to model R&D trending upward in the coming years as treatment candidates advance through development, but anticipate that pivotal Phase III trials will receive partial or full funding from potential partners. We forecast small and incremental increases in SG&A.

StemCells had \$29.9m in cash as of 30 June 2015, up from \$14.1m at the end of Q115, as it shored up its balance sheet through an equity raise earlier in the quarter yielding ~\$25m net. The company's cash runway should enable operations to be funded into 2016. In its recent conference call, StemCells reiterated its intent to seek non-dilutive sources of capital as a primary source of funding. Current outstanding warrants remain a potential future source of cash although, at an exercise price of \$0.42, are out-of-the-money (share price as of 19 August) and are not incorporated into our model.

Exhibit 5: Financial summary

| | \$'000s | 2012 | 2013 | 2014 | 2015e | 2016e |
|---|---------|----------|----------|----------|----------|----------|
| Year-end 31 December | | US GAAP | US GAAP | US GAAP | US GAAP | US GAAP |
| PROFIT & LOSS | | | | | | |
| Revenue | | 1,368 | 1,203 | 1,012 | 171 | 200 |
| Cost of Sales | | (263) | (317) | 0 | 0 | 0 |
| Gross Profit | | 1,105 | 887 | 1,012 | 171 | 200 |
| Research and development | | (15,847) | (20,534) | (21,503) | (23,617) | (24,798) |
| General & administrative | | (7,447) | (8,897) | (10,420) | (10,153) | (10,458) |
| EBITDA | | (23,181) | (29,602) | (32,218) | (35,005) | (36,422) |
| Operating Profit (before GW and except.) | | (22,189) | (28,544) | (30,910) | (33,599) | (35,056) |
| Intangible Amortization | | 0 | 0 | 0 | 0 | 0 |
| Exceptionals/Other | | (356) | (62) | 0 | 0 | 0 |
| Operating Profit | | (22,546) | (28,605) | (30,910) | (33,599) | (35,056) |
| Net Interest | | (35) | (1,155) | (1,287) | (480) | (163) |
| Other (includes change in fair value of warrants) | | (5,911) | 3,322 | (544) | (206) | 0 |
| Profit Before Tax (norm) | | (22,224) | (29,699) | (32,197) | (34,079) | (35,219) |
| Profit Before Tax (FRS 3) | | (28,491) | (26,439) | (32,741) | (34,285) | (35,219) |
| Tax | | 0 | 0 | 0 | 0 | 0 |
| Deferred tax | | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax (norm) | | (22,224) | (29,699) | (32,197) | (34,079) | (35,219) |
| Profit After Tax (FRS 3) | | (28,491) | (26,439) | (32,741) | (34,285) | (35,219) |
| Average Number of Shares Outstanding (m) | | 28.8 | 43.4 | 61.6 | 98.0 | 108.5 |
| EPS - normalized (c) | | (77.0) | (68.2) | (56.3) | (34.6) | (32.5) |
| EPS - FRS 3 (c) | | (77.0) | (68.2) | (56.3) | (34.6) | (32.5) |
| Dividend per share (c) | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| BALANCE SHEET | | | | | | |
| Fixed Assets | | 6,129 | 9,717 | 5,919 | 5,264 | 4,669 |
| Intangible Assets | | 3,806 | 3,975 | 357 | 336 | 336 |
| Tangible Assets | | 1,375 | 5,305 | 5,187 | 4,555 | 3,960 |
| Other | | 947 | 437 | 375 | 373 | 373 |
| Current Assets | | 24,041 | 31,840 | 26,508 | 14,689 | 20,329 |
| Stocks | | 0 | 0 | 0 | 0 | 0 |
| Debtors | | 110 | 109 | 159 | 17 | 17 |
| Cash | | 22,372 | 30,585 | 24,988 | 13,456 | 19,096 |
| Other | | 1,559 | 1,146 | 1,361 | 1,216 | 1,216 |
| Current Liabilities | | (5,097) | (9,132) | (11,498) | (7,858) | (5,113) |
| Creditors | | (4,891) | (5,343) | (6,811) | (5,113) | (5,113) |
| Short term borrowings* | | (206) | (3,789) | (4,686) | (2,745) | 0 |
| Long Term Liabilities | | (11,089) | (17,471) | (15,059) | (5,468) | (45,468) |
| Long term borrowings** | | (125) | (9,245) | (10,324) | (358) | (40,358) |
| Other long term liabilities | | (10,964) | (8,226) | (4,734) | (5,110) | (5,110) |
| Net Assets | | 13,985 | 14,954 | 5,871 | 6,627 | (25,583) |
| CASH FLOW | | | | | | |
| Operating Cash Flow | | (19,819) | (22,895) | (27,352) | (30,769) | (30,712) |
| Net Interest | | (50) | (427) | 0 | (295) | (163) |
| Tax | | 0 | 0 | 0 | 0 | 0 |
| Capex | | (73) | (4,706) | (426) | (752) | (771) |
| Acquisitions/disposals | | 0 | 0 | 0 | 149 | 0 |
| Financing | | 25,949 | 23,683 | 20,425 | 23,350 | 0 |
| Dividends | | 0 | 0 | 0 | 0 | 0 |
| Other | | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | | 6,006 | (4,346) | (7,353) | (8,318) | (31,646) |
| Opening net debt/(cash) | | (16,069) | (22,041) | (17,551) | (9,977) | (10,352) |
| HP finance leases initiated | | 0 | 0 | 0 | 0 | 0 |
| Exchange rate movements | | 16 | 2 | 16 | 0 | 0 |
| Other | | (51) | (146) | (238) | 8,693 | 31 |
| Closing net debt/(cash) | | (22,041) | (17,551) | (9,977) | (10,352) | 21,263 |

Source: StemCells financial reports, Edison Investment Research. Note: *Silicon Valley Bank Loan (\$3.5m outstanding as of 30 June 2015 fully payable by April 2016. **CIRM (California Institute for Regenerative Medicine) loan granted in April 2013: outstanding amount of \$8.9m as of 30 June 2015 is expected to be forgiven in full, in accordance with the terms of the loan agreement (source: 10-Q, 30 June 2015).

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by StemCells and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2015. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.